Sustained Virologic Response
"Sustained Virologic Response" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS.
| Descriptor ID |
D000072230
|
| MeSH Number(s) |
E01.789.800.570 N04.761.559.590.800.665 N05.715.360.575.575.800.665
|
| Concept/Terms |
Sustained Virologic Response- Sustained Virologic Response
- Response, Sustained Virologic
- Sustained Virologic Responses
- Virologic Response, Sustained
- Sustained Viral Suppression
- Suppression, Sustained Viral
- Sustained Viral Suppressions
|
Below are MeSH descriptors whose meaning is more general than "Sustained Virologic Response".
Below are MeSH descriptors whose meaning is more specific than "Sustained Virologic Response".
This graph shows the total number of publications written about "Sustained Virologic Response" by people in this website by year, and whether "Sustained Virologic Response" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sustained Virologic Response" by people in Profiles.
-
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
-
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
-
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
-
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
-
Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? J Infect Dis. 2018 01 30; 217(4):521-528.
-
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
-
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
-
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62.